ATNM vs NVX

For growth investors, Novonix Limited (NVX) is the stronger pick with -51.

8% revenue growth year-over-year, versus -100. 0% for Actinium Pharmaceuticals, Inc. (ATNM). The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Actinium Pharmaceuticals, Inc.

(ATNM) delivered a total return of -83. 3%, compared to -96. 9% for Novonix Limited (NVX). Over 10 years, the gap is even starker: NVX returned -96. 9% versus ATNM's -97. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Actinium Pharmaceuticals, Inc.

(ATNM) is the lower-risk stock at 1. 40β versus Novonix Limited's 1. 90β — meaning NVX is approximately 36% more volatile than ATNM relative to the S&P 500. On balance sheet safety, Actinium Pharmaceuticals, Inc. (ATNM) carries a lower debt/equity ratio of 5% versus 51% for Novonix Limited — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Novonix Limited (NVX) is pulling ahead at -51.

8% versus -100. 0% for Actinium Pharmaceuticals, Inc. (ATNM). On earnings-per-share growth, the picture is similar: Actinium Pharmaceuticals, Inc. grew EPS 30. 6% year-over-year, compared to -7. 1% for Novonix Limited. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Novonix Limited (NVX) is the more profitable company, earning -1278.

0% net margin versus -384. 4% for Actinium Pharmaceuticals, Inc. — meaning it keeps -1278. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NVX leads at -880. 0% versus -414. 9% for ATNM. At the gross margin level — before operating expenses — NVX leads at 69. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Actinium Pharmaceuticals, Inc.

(ATNM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Novonix Limited (NVX) carries a higher beta of 1. 90 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ATNM: -97. 7%, NVX: -96. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (ATNM (Healthcare) and NVX (Industrials)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.